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Abstract
Background—Congenital limb deficiencies (LD)s are characterised by the failure or disruption 
in formation of limbs or digits. Epidemiological research on maternal exposure to cigarette smoke 
and LDs is inconclusive.
Methods—Data from the National Birth Defects Prevention Study were used to examine LDs 
and maternal exposure to active or passive cigarette smoke. Mothers of LD case (n = 906) and 
unaffected control (n = 8352) pregnancies from October 1997 through December 2007 reported on 
exposure type and quantity. Logistic regression was used to estimate adjusted odds ratio (OR) and 
95% confidence interval [95% CI]; interactions with folic acid (FA) intake were tested.
Results—For any LD, ORs were elevated for active (1.24 [95% CI 1.01, 1.53]), passive (home) 
(1.28 [95% CI 1.03, 1.59]), and ‘active and passive’ (1.34 [95% CI 1.05, 1.70]) exposures. The 
ORs for longitudinal LDs were elevated for passive (home) (1.62 [95% CI 1.14, 2.31]) and ‘active 
and passive’ (1.62 [95% CI 1.09, 2.41]) exposures. The OR for pre-axial LDs were elevated for 
any (1.39 [95% CI 1.01, 1.90]), active (1.53 [95% CI 1.03, 2.29]), passive (home) (1.82 [95% CI 
1.23, 2.69]), and ‘active and passive’ (1.87 [95% CI 1.20, 2.92]) exposures. For lower limbs, ORs 
were elevated for passive (home) (1.44 [95% CI 1.01, 2.04]) and smoking 15 or more 
cigarettes/day (2.25 [95% CI 1.27, 3.97]). Interactions showed that ORs for any passive smoke 
exposure were 0.43 and 0.59 higher in the absence of FA intake for any and terminal transverse 
LDs.
Conclusions—Maternal active smoking and exposure to passive cigarette smoke emerged as a 
potential teratogen that affects limb and digit formation. FA was not found to mitigate the impact.
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Limb deficiencies (LD)s are characterised by the failure in formation or disruption of a 
portion of the entire upper or lower limb or digits during foetal development; the prevalence 
of LDs is estimated to be 5–8 per 10 000 live births.1 Limb development in the human 
embryo begins as early as 4 weeks after conception; upper limb buds first appear on the 26th 
day and lower limb buds on the 28th day. The limb buds, which consist of mesenchymal 
core and ectodermal cells, differentiate into muscle, cartilage, and bone. At around the sixth 
week, the hand and foot plates form and separate from the limb buds; thus, the first trimester 
marks an important period during which various factors can lead to malformations in limb 
development.
The majority of LDs appear as isolated defects with 12–33% occurring with other major 
congenital malformations.1 Terminal transverse LDs are the most common subtype followed 
by split hand/foot, longitudinal, intercalary, and mixed. Vascular disruption resulting in 
foetal hypoxia has been implicated in the pathogenesis of LDs.2–5 There are several known 
contributors to the development of foetal hypoxia, including maternal exposure to cigarette 
smoke during pregnancy from either active smoking6 or passive cigarette smoke.7 Studies 
examining the relation between maternal exposure to cigarette smoke and LDs have been 
inconsistent with elevated odds ratios (ORs) reported for some,8–11 but not all LD 
subtypes.8,10,12–14 Fewer studies have assessed passive smoke exposure, and, of those 
identified, the findings have also been equivocal.12–14 Comparison across studies is difficult, 
however, due to variation in the inclusion of covariables, LD subtypes examined, and type 
of cigarette smoke exposure (e.g. active or passive) measured.
Because a substantial number of pregnant women continue to be directly15 and indirectly 
exposed to cigarette smoke,16 data from the National Birth Defects Prevention Study 
(NBDPS), a large population-based case–control study, were used to examine the relation 
between maternal exposure to cigarette smoke and LDs. Associations between different 
types of maternal exposure to cigarette smoke and LD subtypes were examined while 
controlling for important covariables (e.g. alcohol consumption, intake of vasoactive 
medications and vitamin A). In addition, there is evidence suggesting that folic acid (FA) 
supplementation may mitigate the potential teratogenic effects of exposure to cigarette 
smoke on adverse foetal outcomes.17,18 Therefore, the interaction between FA supplement 
intake and exposure to cigarette smoke was tested.
Methods
Sample selection, case classification, and recruitment
The NBDPS is an ongoing, multisite, population-based, case–control study designed to 
investigate genetic and environmental risk factors for 37 major birth defect groups. Initial 
NBDPS sites included birth defect surveillance systems in seven states [Arkansas (AR), 
California (CA), Iowa (IA), Massachusetts (MA), New Jersey (NJ), New York (NY), and 
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Texas (TX)], as well as at the Centers for Disease Control and Prevention (CDC) in Georgia. 
In 2002, surveillance systems in two additional states [North Carolina (NC) and Utah (UT)] 
were included in the NBDPS. Sites contributed live births diagnosed with LDs and a limited 
number of sites ascertained foetal deaths (AR, CA, CDC, IA, MA, TX, and NY since 2000) 
and elective terminations (AR, CA, CDC, IA, TX, and NY since 2000). Each site obtained 
institutional review board approval for the NBDPS.
Control pregnancies were unaffected live births with an estimated date of delivery (EDD) 
during the same time frames as case pregnancies and randomly selected from either hospital 
delivery logs (AR and CDC 1997–2000; CA, NY, TX 1997–2007) or birth certificate files 
(AR 2000-07; CDC 2001-07; IA, MA, NC, NJ, and UT 1997–2007). Excluded were cases 
with defects of known or strongly suspected genetic aetiology (e.g. single gene disorders and 
chromosome abnormalities), cases and controls not in the custody of or not residing with 
their birth mothers, or cases and controls whose birth mother did not speak English or 
Spanish.
Case classification
Case classification was determined by local clinical geneticists at each NBDPS site using 
clinical information abstracted from medical records and compiled in a centralised clinical 
database. Clinical information on each pregnancy used to determine case classification 
included: method of diagnosis (i.e. a diagnosis of a cardiac defect required results from an 
echocardiography, catheterisation, surgery, or autopsy); laboratory results, including 
genetics and other specialty evaluations when available; and relevant exposures or presence 
of family history. Clinical geneticists reviewed available clinical information for each case 
pregnancy and assigned standard case definitions to determine case status. Additional 
information about case classification can be found in Rasmussen et al.19 An NBDPS-
specific modification of the CDC six-digit coding system was assigned to each case meeting 
definitional criteria. The development of the NBDPS codes and their relation to the 
International Statistical Classification of Diseases and Related Health Problems (ICD-9), the 
clinical modification of the ICD-9, and British Paediatric Association coding schemes can 
be found in Rasmussen and Moore.20 The NBDPS codes were developed because of a lack 
of specificity of existing codes for certain LD subtypes (e.g. split hand or foot codes).
Case classification by site clinical geneticists was reviewed by a NBDPS clinical geneticist 
(R.S.O.) to ensure consistency in coding and to further classify eligible cases as isolated (no 
additional major and unrelated defects), multiple (one or more additional major and 
unrelated defects), or complex sequence (i.e. limb-body wall complex and amniotic bands).
Cases were classified into the following subtypes: longitudinal (pre-axial, post-axial, and 
split hand/ foot), terminal transverse (amelia excluded), amelia, intercalary, and not 
elsewhere classified. LDs were also classified in terms of laterality and sidedness of the 
deficiency (unilateral-left, unilateral-right, bilateral, and unknown), and whether an upper or 
lower limb was affected. To reduce pathogenetic heterogeneity, cases with amniotic band 
syndrome (n = 162) or any other complex sequence (n = 1) were excluded.
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Structured, computer-assisted telephone interviews were conducted with birth mothers of 
cases and controls; interviews were conducted from 6 weeks to 2 years following the EDD. 
Median length between EDD and interview date was 9.0 months for case mothers and 7.6 
months for control mothers. A standard protocol was followed for recruitment of case and 
control mothers.21 Specifically, mothers were mailed a packet that included an introductory 
letter describing the study, $20 compensation, and interview-related materials (i.e. a sheet 
listing response categories and a pregnancy calendar). The packet was mailed no earlier than 
6 weeks following the EDD. The recruitment protocol consisted of an 8-week follow-up 
period after the initial mailing of the introductory letter. Three additional attempts to reach 
the mother were made at 2-week intervals and consisted of a series of follow-up telephone 
calls or reminder letters if contact was not made by phone. If no contact was made during 
the 8-week recruitment period, then the mother was counted as a non-participant.
Maternal interview
The interview included, but was not limited to, detailed questions about health problems, 
single and multiple vitamin intake, medication use, alcohol consumption, and maternal 
exposure to cigarette smoke from 3 months before conception through the end of the 
pregnancy. For each, the mother was asked for dates of occurrence and, where applicable, 
the frequency with which the exposure occurred. From these questions, we derived maternal 
periconceptional exposures to the following covariables: vitamin A from either a single 
vitamin or multivitamin; vasoactive medications, which included antihypertensives (0.1%), 
bronchodilators (4.1%), decongestants (10.3%), migraine medications (0.6%), and non-
steroidal anti-inflammatory drugs (32.4%); and alcohol consumption.
Exposure assessments
Periconceptional exposure to cigarette smoke—Retrospective reports for cigarette 
smoke exposure were collected for each of the 3 months prior to pregnancy (labelled B3, 
B2, and B1), each of the first 3 months of pregnancy (labelled M1, M2, and M3), and by 
trimester for months 4–6 and 7–9 of pregnancy (labelled T2 and T3). Maternal exposure to 
cigarette smoke was classified as active (mother herself smoked) or passive (exposure to 
smoke at home or in the workplace). If a mother reported active smoking, information about 
the average number of cigarettes smoked per day [frequency categories: <1, 1, 2–4, 5–14 
(one-half pack), 15–24 (one pack), 25–34 (one and one-half packs), 35–44 (two packs), and 
≥45], and the month(s) of exposure were collected. A mother was classified as exposed to 
passive cigarette smoke in the home if she answered yes to the question ‘Did anyone in your 
household smoke cigarettes in your home between 3 months before you became pregnant to 
the end of your pregnancy?’ and exposed to passive cigarette smoke in the workplace or 
school if she said yes to ‘Did anyone smoke cigarettes near you at a work-place or school 
you may have attended during that year?’. If a mother reported passive exposure to smoke, 
information about the periconceptional month(s) during which exposure at home or work/ 
school occurred was collected.
A mother was classified as exposed to cigarette smoke if she reported active or passive 
smoke exposure during any month of the periconceptional period [defined as 1 month before 
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conception (B1) through the first 3 months following conception (M1, M2, and M3)]. 
Reported exposure to cigarette smoke was also classified by type of exposure (active only, 
passive only, or ‘active and passive’). Among mothers who reported active smoking, 
exposure was further classified by number of cigarettes smoked per day (1–14 per day vs. 
≥15 per day). Duration of exposure was estimated separately for exposure to any active or 
any passive cigarette smoke (number of periconceptional months exposed, 0 through 4), 
with each month considered to be of equal exposure value; thus, duration was assigned a 
value of 1 whether a mother reported exposure during B1, M1, M2, or M3 only.
Periconceptional FA supplementation—Periconceptional FA supplementation was 
determined from interview questions asking about the use of pre-natal vitamins, 
multivitamins, and intake of specific vitamins or minerals from 3 months before conception 
through the end of the pregnancy. Follow-up questions about timing and frequency of intake 
were asked for each reported prenatal vitamin, multivitamin, or single vitamin/mineral. 
These follow-up probes included questions about start and stop dates of use and frequency 
of intake (e.g. once per day). Mothers were classified as using a FA supplement during the 
4-month periconceptional period (B1–M3) if a supplement was taken at least 90 out of the 
possible 120 days. Ninety days was assigned as the minimum cut-off for use because many 
women do not initiate FA supplement intake until after knowledge of pregnancy.
Statistical analysis
Analyses were conducted using SAS, version 9.2 (SAS Institute, Cary, NC, USA). 
Descriptive analyses used the chi-square test to compare cases and controls on the following 
covariables: case and control sex (male and female), low birthweight (<2500 and ≥2500 g), 
preterm delivery (<37 and 37–45 weeks), and family history of LD (yes and no); maternal 
age (<20, 20–34 and ≥35 years), race/ethnicity (non-Hispanic white, non-Hispanic black, 
Hispanic, and other), education (<12, 12, 13–15, and ≥16 years), pre-pregnancy body mass 
index (<18.5, 18.5–24.9, 25.0–29.9 and ≥30), and parity (no prior births, primipara, and 
multipara); plurality (singleton and multiple) and pregnancy intention (yes and no); maternal 
periconceptional exposure to contraceptive pills (yes and no), FA or multivitamin (yes and 
no), and vitamin A (yes and no), vasoactive medications (0, 1, and 2 or more), and alcohol 
(yes and no); season of conception (summer, fall, winter, and spring); and NBDPS site.
Crude OR (cOR), adjusted OR (aOR), and associated 95% confidence intervals (CI) were 
calculated to assess associations between LDs and maternal exposure to cigarette smoke. 
The significance of multiplicative and additive interactions [e.g. the relative excess risk 
interval (RERI)] between selected maternal cigarette smoke exposure variables and FA 
supplementation were also tested. Bootstrapping methods were used to estimate the 
interaction terms and corresponding significance tests; P-values were used to determine 
significance of the multiplicative interaction estimate, and 95% CI were used for the RERI 
estimates.22 [The RERI and 95% CI were calculated by bootstrapping methods using a SAS 
macro developed by Marilyn Browne and Sandra Richardson (2011, pers. comm., New 
York State Department of Health)].
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Possible confounding was examined by introducing each covariable into a model containing 
the exposure variable of interest. The respective covariable was included in the multivariable 
model if any aOR for cigarette smoke exposure changed by 10% or more after adding the 
covariable. Adjusted analyses are only presented for LD subtype groups containing at least 
100 cases (i.e. any LD, any longitudinal LD, pre-axial LD, and terminal transverse). 
Analyses for LD subtypes with fewer than 100 cases are available in the supplementary 
tables.
Results
Participation in the maternal interview was 69% among case mothers and 65% among 
control mothers. A total of 906 case mothers and 8352 control mothers completed 
interviews. Overall, the most common LD subtype was terminal transverse; intercalary and 
amelia LDs were least frequent (Table 1). Approximately one half of all cases were affected 
on the left side, followed by right-sided and bilateral presentation. Most of the affected 
limbs were the arms. The presence of other major congenital defects differed by LD 
subtype; any longitudinal, pre-axial, and amelia subtypes were more likely than other LD 
subtypes to have multiple defects; all other subtypes were mostly isolated defects.
Cases were more likely than controls to be male, low birthweight, preterm, and have a 
family history of LDs (Table 2). Case mothers were more likely to be Hispanic and have 
fewer years of education. Case pregnancies were more likely to be the mother’s first birth, a 
multiple pregnancy, and unintended. Maternal periconceptional exposures to vitamin A, 
vasoactive medication, and alcohol were more common among case mothers compared with 
control mothers. Case pregnancies were more often conceived in the winter, and variation 
across site was also found. No differences between case and control mothers were found for 
maternal age at EDD and pre-pregnancy body mass index or maternal periconceptional 
exposure to contraceptive pills and FA or multivitamins.
Case and control mothers reported similar exposures to any periconceptional cigarette 
smoke and active smoking. Case mothers were more likely to report exposure to passive 
cigarette smoke, with or without active smoking (Table 3). Proportions of case and control 
mothers reporting specific types of smoke exposure (‘active only’, ‘passive only’, and 
‘active and passive’), duration of ‘active and passive’ smoke, and the number of average 
cigarettes smoked per day by mothers who reported active smoking were similar. Among 
those exposed to cigarette smoke, passive smoke only was the most common mode of 
exposure (43.1%) followed by ‘active and passive’ (35.7%) and ‘active only’ (21.2%). Of 
mothers reporting active smoking, over one half (53.8%) smoked all four months of the 
periconceptional period. Most mothers (85.1%) that reported passive exposure (home or 
work) were exposed all 4 months. To evaluate possible response bias, case and control 
mothers were compared on changes in reported frequency of cigarette smoke exposure after 
pregnancy recognition and by 6-month intervals between EDD and date of interview. No 
response bias was found (data not shown).
aORs showed that case and control mothers differed on several indicators of exposure to 
cigarette smoke (see Table 4). The aORs for any exposure to cigarette smoke and active 
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smoke were significantly elevated for any LD and pre-axial longitudinal LDs. Odds of 
passive exposure in the home were elevated for any LD, any longitudinal LD, and pre-axial 
longitudinal LDs. Odds of exposure to ‘active and passive’ cigarette smoke were elevated 
for any LD, any longitudinal LD, and the pre-axial longitudinal LD subtype. Terminal 
transverse LDs were not significantly associated with any indicator of periconceptional 
exposure to cigarette smoke. Odds of passive exposure to cigarette smoke in the home and 
actively smoking greater than 15 cigarettes a day were higher for cases with affected lower 
limbs (see Table 5). Adjusted analyses for duration of exposure to active smoking and 
passive smoke in the home could only be reliably estimated for any LD for which no 
associations were found (data not shown).
The mitigation of the association of cigarette smoke cigarette exposure on limb development 
by FA supplementation was examined. To maximise power, the cigarette smoke exposure 
variables were limited to: any cigarette smoke; active smoking only; any passive (home or 
work) cigarette smoke only; and ‘active and passive’ (home or work) cigarette smoke. No 
exposure to ‘active and passive’ cigarette smoke was the reference group for each exposure. 
Tests of the multiplicative interactions were not significant for any of the LD subtypes 
evaluated (data not shown). The RERIs calculated for additive interactions between 
exposure to passive (home or work) smoke only and FA supplementation were significant 
for any LD and the terminal transverse subtype. The risk ratio (RR) for passive (home or 
work) cigarette smoke exposure and any LD was 0.74 [95% CI 0.45, 1.16] among mothers 
who supplemented with FA, and the RR for exposure among mothers who did not 
supplement was 1.18 [95% CI 0.93, 1.49]. The RERI between mothers who did and did not 
use FA supplements was significant (RERI = 1.18–0.74 = 0.43 [95% CI 0.04, 0.78]), 
indicating higher RR among mothers who were exposed to any passive (home or work) 
cigarette smoke and did not take FA supplements compared with exposed mothers who did 
take supplements. Similarly, the RR for terminal transverse was 0.61 [95% CI 0.33, 1.14] 
among mothers who used FA supplements and 1.22 [95% CI 0.90, 1.65] among mothers 
who did not take supplements; the statistically significant RERI was 0.59 [95% CI 0.10, 
0.99]. The non-significant RERIs for the pre-axial subtype and upper or lower affected limbs 
suggests FA supplementation does not mitigate the associations of cigarette smoke exposure 
with these LDs.
Comments
Maternal reports of exposure to cigarette smoke were compared between mothers of cases 
diagnosed with LDs and mothers of non-malformed controls. Odds of exposure to active 
cigarette smoke, passive (home) smoke, and combined exposure to multiple types of 
cigarette smoke were higher among mothers of cases diagnosed with any LD, any 
longitudinal LD, and the pre-axial longitudinal LD subtype. Analysis of upper and lower 
affected limbs (regardless of subtype) showed elevated ORs for exposure to passive 
cigarette smoke and actively smoking 15 or more cigarettes a day for lower limbs only. 
Analyses for effect modification of exposure to cigarette smoke by FA supplement intake 
showed higher cORs among mothers who were exposed to cigarette smoke but did not take 
FA supplements. Statistical tests of the interactions, however, only showed significant 
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additive interactions for any LD and the terminal transverse subtype with higher cOR for 
exposure to cigarette smoke in the absence of FA supplementation.
The absence of an association between maternal exposure to cigarette smoke and terminal 
transverse LDs is consistent with findings presented by Werler et al.,10 which analysed 
NBDPS data collected between 1998 and 2004, but contrary to two previous independent 
studies that showed higher odds of maternal exposure to cigarette smoke among cases born 
with terminal transverse LDs.8,9 The findings in this study are also inconsistent with Källen8 
and Czeizel et al.9 because of the demonstrated associations between maternal reports of 
exposure to cigarette smoke and the pre-axial LD not found in the previous studies. The 
discrepancy between studies could be due in part to the collapsing of LD subtypes into 
broader categories. For example, Källen8 examined associations between maternal active 
smoking and combined LD subtypes into broader classes (e.g. any longitudinal). The overall 
diagnosis of longitudinal LD was not associated with exposure to active cigarette smoke; 
only ORs for the pre-axial longitudinal LD subtype were elevated. Another possible reason 
for discrepancies could be that neither Källen8 nor Czeizel et al.9 assessed maternal 
exposure to passive smoke, which was predictive in this study. The finding of higher odds of 
passive exposure among mothers of LD cases is consistent with one other study that 
included assessment of paternal cigarette smoking.12 Finally, the inconsistencies with other 
findings could be due, in part, to changes in the classification scheme of LDs that have 
occurred over the years, making direct comparisons of findings difficult.
There are multiple biological mechanisms that could account for the observed associations 
between exposure to cigarette smoke and LDs. One is that exposure to cigarette smoke may 
contribute to LDs because of the increased likelihood of chronic foetal hypoxia.5 Chronic 
hypoxia is hypothesised to trigger a ‘lower limb reflex’,23 which is a compensatory 
mechanism by which circulatory flow is directed away from the vascular beds of the lower 
limb, skeletal muscles, skin, and mesentery, and towards the foetal heart and brain.24 This 
vasoconstriction may result in cell death or haemodynamic changes that can impact delivery 
of vital nutrients. The ‘lower limb reflex’ hypothesis is consistent with the findings of 
elevated odds of maternal exposure to cigarette smoke among infants having lower LDs and 
is supported by studies suggesting an association between other lower limb structural defects 
and maternal exposure to cigarette smoke (e.g. clubfoot/talipes equinovarus).25
Another plausible mechanism is the effect of homocysteine on retinol conversion. Animal 
models have shown a dose-dependent association between the induction of congenital 
defects and hyperhomocysteinemia.26 Homocysteine has been shown to be elevated among 
smokers,27 including pregnant women28,29 and non-smokers exposed to passive cigarette 
smoke.30 Hyperhomocysteinemia interferes with the conversion of retinol to retinoic acid 
and signalling by retinoic acid receptors.26 Retinoic acid is important to skeletal 
development because it controls developmental genes and acts as a morphogen.31 
Morphogens are essential to informing cells of where they are located (i.e. limbs) and their 
purpose (i.e. digits). Retinoic acid is also key to the regulation (e.g. turning on) of the sonic 
hedgehog gene,32 which polarises the zone of polarising activity and activates Hoxd gene 
activity in a sequential transcriptional pattern. Interference with the actions of the zone of 
polarising activity and Hoxd can subsequently affect limb patterning and development.
Caspers et al. Page 8













Limitations of the study included small numbers for specific LD subtypes (i.e. post-axial, 
split hand or foot, and amelia). Even though the exposure assessment improves upon 
methods of previous studies (e.g. birth certificates), the use of retrospective maternal reports 
may introduce response bias by underestimating exposures due to active maternal smoking. 
However, potential response bias was evaluated by examining differences between case and 
control mothers on changes in rates of exposure to cigarette smoke over the periconceptional 
period, after recognition of pregnancy, or as a function of time between EDD and date of 
interview. Although none of the comparisons were statistically significant, evaluations of 
biological markers not available in the NBDPS are needed to provide a more definitive 
evaluation of response bias. Another limitation is the measurement of frequency or average 
number of cigarettes. The number of cigarettes smoked per day was collected in categories, 
which prohibited detailed examination of dose–response associations between LDs and 
number of cigarettes actively smoked. In addition, the assessment of exposure to passive 
cigarette smoke was less exhaustive than that for active cigarette smoking. Questions were 
limited to location exposed (home or work) and did not gather detailed information about 
frequency and intensity of exposure; furthermore, changes in work policies on smoking in 
the workplace could not be systematically evaluated. Finally, this study attempted to include 
important covariables reported in previous studies of LDs; however, the occurrence of some 
(i.e. chorionic villus sampling and migraines) were too rare to analyse.
Strengths of the study included analysis of multiple LD subtypes, detailed assessment of 
exposure to active cigarette smoke, and detailed examination of important covariables. 
Analysis of individual LD subtypes showed associations between specific LD subtypes and 
periconceptional maternal exposure to cigarette smoke; although the results should be 
replicated using larger samples for subtypes. With regard to cigarette smoke, information 
was collected about frequency and duration of exposure, as well as passive exposure at 
home and work. This information provides a more complete understanding of the degree of 
exposure among pregnancies affected by LDs. Another strength was the extensive set of 
covariables evaluated, which allowed examination of cigarette smoke exposure after 
controlling for other potential factors involved in LDs (e.g. vasoactive medication use).
Based on the findings, maternal exposure to cigarette smoke during the periconceptional 
period is a potential teratogen that affects limb and digit formation, and FA supplement 
intake was not found to mitigate the impact. Importantly, this study suggests that passive 
exposure to cigarette smoke might affect limb development regardless of maternal active 
smoking status. These findings add to a growing literature on passive smoke exposure and 
adverse foetal outcomes. Because of multiple, albeit correlated, comparisons that increase 
the likelihood of significant findings due to chance, additional research is needed to replicate 
these findings using larger sample sizes to explore specific pathogenic mechanisms and 
examine potential interventions to reduce toxicity of exposure.
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Table 2




No. % No. %
Totals 8352 906
Case and control characteristics
 Sex***
  Female 4102 49.2 386 43.0
  Male 4242 50.8 512 57.0
 Low birthweight ***
  <2500 g 466 5.6 233 25.9
  ≥2500 g 7851 94.4 667 74.1
 Preterm delivery***
  Term (37–45 weeks) 7564 90.6 666 73.9
  Preterm (<37 weeks) 787 9.4 235 26.1
 Family history of LD***
  Yes 11 0.1 7 0.8
  No 8341 99.9 899 99.2
Maternal characteristics
 Age at EDD (years)
  <20 856 10.3 100 11.0
  20–34 6322 75.7 696 76.8
  ≥35 1174 14.1 110 12.1
 Race/ethnicity**
  Non-Hispanic white 4942 59.4 507 56.0
  Non-Hispanic black 927 11.1 89 9.8
  Hispanic 1908 22.9 254 28.1
  Other 545 6.6 55 6.1
 Education (years)*
  <12 1429 17.1 162 17.9
  12 2017 24.2 245 27.1
  13–15 2260 27.1 256 28.3
  16 or more 2937 31.6 242 26.7
 Pre-pregnancy body mass index
  Underweight (<18.5) 433 5.4 49 5.7
  Normal weight (18.5–24.9) 4405 55.0 447 52.0
  Overweight (25.0–29.9) 1830 22.8 204 23.7
  Obese (≥30) 1343 16.8 160 18.6
 Parity*
  Never pregnant 2435 29.2 302 33.3
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Characteristic
Controls Any LD
No. % No. %
  Primipara 2455 29.4 261 28.8
  Multipara 3461 41.4 343 37.9
Maternal pregnancy characteristics
 Plurality***
  Multiple 251 3.0 57 6.3
  Singleton 8096 97.0 849 93.7
 Pregnancy Intention**
  Yes 5051 60.7 506 56.2
  No 3277 39.4 395 43.8
Maternal periconceptional behaviours
 Contraceptive pill use
  Yes 640 7.7 74 8.2
  No 7712 82.3 832 91.8
 Folic acid/multivitamin intake
  Yes 3040 36.4 323 35.6
  No 5312 63.6 583 64.4
 Vitamin A intake*
  Yes 3931 47.2 389 43.2
  No 4390 52.8 511 56.8
 Vasoactive medication intake***
  0 5388 65.9 550 61.9
  1 2279 27.9 250 28.2
  2 or more 510 6.2 88 9.9
 Alcohol use**
  No 5239 63.3 610 68.1
  Yes 3041 36.7 286 31.9
Season of conception*
 Fall 2163 25.9 232 25.6
 Winter 2079 24.9 254 28.0
 Spring 2041 24.4 231 25.5
 Summer 2069 24.8 189 20.9
Study site***
 Arkansas 1055 12.6 92 10.2
 California 1017 12.2 143 15.8
 Iowa 928 11.1 89 9.8
 Massachusetts 1027 12.3 110 12.1
 New Jersey 573 6.9 84 9.3
 New York 722 8.6 63 7.0
 Texas 969 11.6 109 12.0
 Center for Disease Control and Prevention 880 10.5 91 10.0
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Characteristic
Controls Any LD
No. % No. %
 North Carolina 570 6.8 37 4.1







Numbers vary because of incomplete or missing data. Because of rounding, percentages may not total 100.
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Table 3
Maternal periconceptional exposure to cigarette smoke and limb deficiencies, National Birth Defects 
Prevention Study (1997–2007)
Cigarette smoking exposure
Controls (n = 8352) Any LD (n = 906)
No. % No. %
Any active or passive
 No active or passive 5664 68.0 589 65.3
 Active or passive 2666 32.0 313 34.7
Any active
 No active or passive 5664 78.7 589 75.7
 Activea 1537 21.3 189 24.3
Any passive (home)
 No active or passive 5664 82.2 589 79.1
 Passive (home)b 1231 17.9 156 20.9
Any passive (work)
 No active or passive 5664 83.2 589 81.6
 Passive (work)c 1148 16.9 133 18.4
Type of smoke
 No active or passive 5664 68.1 589 65.3
 Active only 626 7.5 73 8.1
 Passive only (home or work) 1126 13.5 124 13.8
 Active and passive 906 10.9 116 12.9
Cigarettes/daya
 No active or passive 5664 78.8 589 75.8
 1–14/day 1270 17.7 154 19.8
 ≥15/day 253 3.5 34 4.4
Duration of active smoking
 No active or passive 5664 78.7 589 75.7
 1 month 217 3.0 26 3.3
 2 months 324 4.5 42 5.4
 3 months 177 2.5 20 2.6
 4 months 819 11.4 101 13.0
Duration of passive (home) smoke
 No active or passive 5664 73.6 589 71.1
 1 month 139 1.8 10 1.2
 2 months 116 1.5 14 1.7
 3 months 95 1.2 10 1.2
 4 months 1685 21.9 206 24.9
No., number of cases or controls.
Numbers vary because of incomplete or missing data. Due to rounding, percentages may not total 100.
a
May include mothers who report exposure to passive (home or work) cigarette smoke.
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b
May include mothers who report exposure to active or passive (work) cigarette smoke.
c
May include mothers who report exposure to active or passive (home) cigarette smoke.
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